India, Feb. 26 -- Actinium Pharmaceuticals, Inc. (ATNM), a developer of targeted radiotherapies, reported Monday new analyses from the positive Phase 3 SIERRA trial of Iomab-B, showing that it markedly increased long term survival in patients 65 years or older with active relapsed or refractory acute myeloid leukemia or r/r AML.
In pre-market activity on the NYSE, Actinium shares were gaining around 2 percent to trade at $7.
The analyses were reported in oral presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT (American Society for Transplantation and Cellular Therapy and CIBMTR (Center for International Blood and Marrow Transplant Research).
The company noted that the presentations repo...